- ASCO 2025
ASCO 2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
Donwload Press release (PDF) - Presentation
Transgene in a nutshell
Corporate Presentation
Universal Registration Document